betaine
Approved
Jul 28, 1972
Betaine is a methyl derivative of glycine first isolated from the juice of sugar beets. Betaine is found in many common foods, but concentrated significantly in beets, spinach, wheat foods, and shellfish. In addition, betaine can be synthesized within the human body. Betaine participates in the methionine cycle, which produces vital biomolecules including proteins, hormones, phospholipids, polyamines, and nutrients. Betaine is used as a dietary supplement and has a beneficial effect on the human health. In the USA, FDA approved a betaine-containing drug Cystadane for the treatment of homocystinuria. The drug acts as a methyl group donor in the remethylation of homocysteine to methionine. — NCATS
Clinical trial activity
39 trials · 45 clinical orgs · 7 marketing orgs
Earliest trial started Jan 1, 2003 (NCT00586911)
Timeline
1970s
- Jul 28, 1972
Earliest FDA Approval
1990s
- May 16, 1994
Orphan Drug Designation
- Oct 25, 1996
Recordati — Marketing Organization
- Oct 25, 1996
Orphan Europe — NDA Secondary Org
- Oct 25, 1996
Recordati — NDA Secondary Org
2010s
- Jan 1, 2011
Earliest Phase 3 Sponsor(trial)
2020s
- Nov 23, 2021
Novitium Pharma — Marketing Organization
- Nov 23, 2021
Ani Pharmaceuticals — Marketing Organization
- Jan 28, 2022
Lukare Medical — Marketing Organization
- Jan 28, 2022
Eton Pharmaceuticals, Inc. — Marketing Organization
Indications
Approved for
Studied for
- Antimetabolites · Phase 4
- Choline · Phase 1
- Depressive Disorder · Phase 4
- Dysbiosis · Phase 2/Phase 3
- Dyslipidemias · Phase 1/Phase 2
- Gallbladder · Phase 2
- Healthy Volunteers · Phase 1
- Hepatitis C · Phase 2/Phase 3
- Hepatitis C, Chronic · Early Phase 1
- Homocystinuria · Phase 2
- Hyperglycemia · Phase 2
- Hyperhomocysteinemia · Phase 3
- Hyperoxaluria · Phase 2
- Infertility, Male · Phase 1
- Intestinal Diseases · Phase 4
- Ligaments · Early Phase 1
- Non-alcoholic Fatty Liver Disease · Phase 2
- Obesity · Phase 2
- Peroxisomes · Phase 3
- Recurrence · Early Phase 1
- Sports · Phase 2/Phase 3
- Surgical Wound · Phase 4
- Surgical Wound Infection · Phase 4
- Syringomyelia · Phase 2
- Xerostomia · Phase 3
Mechanism of action
- Unspecified targetOTHER
Unknown
Chloral betaine is a sedative-hypnotic drug. It is a betaine complex with chloral hydrate, which acts as an extended-acting formulation of chloral hydrate which is then metabolized into trichloroethanol, which is responsible for most or all of its effects. Chloral hydrate mechanism of action is still unknown, but it is believed that its sedative effect is mediated by the Gamma Aminobutyric Acid-A receptors.
Betaine-homocysteine S-methyltransferase substrate
Approval history
- approvedPriority reviewJul 28, 1972
Chemistry & pharmacology
SMILES
C[N+](C)(C)CC(=O)O- Mol. weight
- 118.16 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL95889 ↗
- WikipediaTrimethylglycine ↗
- NCATS3SCV180C9W ↗
- ChEMBLCHEMBL3833335 ↗
- ChEMBLCHEMBL1201130 ↗
- NCATS8680278NRH ↗
Also known as
- 2-n,n,n-trimethylammonio acetate
- 2-n,n,n-trimethylammonio acetate
- 2-trimethylammonioacetate
- 2-trimethylammonioacetate
- 2-(trimethylammonio)acetate
- 2-(trimethylammonio)acetate
- 5107
- abromine
- abromine
- acidol
- acidol
- acidol pepsin
- acidol pepsin
- betafin
- betaine
- betaine
- betaine
- betaine
- betaine
- betaine
- betaine
- betaine
- betaine
- betaine
- betaine anhydrous
- betaine anhydrous
- betaine, anhydrous
- betaine, anhydrous
- betaine chloride
- betaine hcl
- betaine hcl
- betaine hcl
- betaine hydrochloride
- betaine hydrochloride
- betaine hydrochloride
- betaine hydrochloride
- chloral betaine
- chloral betaine
- chloral betaine
- chloral betaine
- cloral betaine
- cloral betaine
- cloral betaine
- cystadane
- cystadane
- cystadane
- cystadane
- cystadane
- glycinebetaine
- glycinebetaine
- glycine betaine
- glycine betaine
- glycine betaine
- glycine betaine
- lycine hcl
- lycine hcl
- n,n,n-trimethylammonioacetate
- n,n,n-trimethylammonioacetate
- n,n,n-trimethylglycine
- n,n,n-trimethylglycine
- oxyneurine
- tmg
- tmg
- trimethylaminoacetate
- trimethylaminoacetate
- trimethylammonioacetate
- trimethylammonioacetate
- trimethylglycine
- trimethylglycine
- trimethylglycocoll
- trimethylglycocoll
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07276204 | Phase 2 | Mar 31, 2026 | Department of Veteran Affairs |
| NCT07243678 | N/A | Dec 31, 2025 | Fundació Sant Joan de Déu |
| NCT07144527 | N/A | Sep 15, 2025 | Concordia University |
| NCT06392360 | N/A | Aug 13, 2024 | Appalachian State University |
| NCT06344377 | N/A | Apr 21, 2024 | Poznan University |
| NCT06308367 | Phase 2 | Mar 31, 2024 | Capital Medical University |
| NCT06309368 | Phase 4 | Mar 14, 2024 | University of Nevada, Las Vegas |
| NCT06042270 | N/A | Jan 31, 2024 | Florida State University |
| NCT05635929 | N/A | Oct 11, 2022 | Mucosa Innovations, S.L. |
| NCT05463484 | Phase 2/Phase 3 (Phase 3) | Jul 13, 2021 | Mucosa Innovations, S.L., University of Granada |
| NCT05790070 | N/A | Feb 1, 2021 | Baylor University |
| NCT04633044 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Fundació Sant Joan de Déu |
| NCT04585295 | N/A | Jan 21, 2020 | Florida State University, NOW Foods |
| NCT03702205 | Phase 2/Phase 3 (Phase 3) | Oct 15, 2018 | National Science Centre, Poland, Poznan University |
| NCT03337360 | N/A | Apr 23, 2018 | Goodlife Fertility B.V., Radboud University |
| NCT05342272 | Phase 3 | Sep 22, 2017 | Spedali Civili di Brescia, University of Brescia |
| NCT02837367 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2016 | Romania:The National Authority for Scientific Research, University of Medicine and Pharmacy Victor Babes Timisoara |
| NCT02758015 | N/A | Jun 1, 2016 | University of California, San Francisco |
| NCT02404337 | Phase 2 | Jul 1, 2015 | University of Paris |
| NCT02403804 | N/A | Apr 1, 2015 | University of Colorado, University of Colorado, Denver |
Organizations
Research & Development (45)
Marketing (8)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Ani Pharmaceuticals | For profit | MKTG | Nov 23, 2021 |
| Eton Pharmaceuticals, Inc. | For profit | MKTG | Jan 28, 2022 |
| Lukare Medical | For profit | MKTG | Jan 28, 2022 |
| Novitium Pharma | For profit | MKTG | Nov 23, 2021 |
| Orphan Europe | For profit | NDA2 | Oct 25, 1996 |
| Orphan Medical | For profit | NDA | — |
| Recordati | For profit | MKTG | Oct 25, 1996 |
| Recordati | For profit | NDA2 | Oct 25, 1996 |